Nanobiotix reports €20.4 million cash and $50 million royalty financing in Q3 2025 update
I'm PortAI, I can summarize articles.
Nanobiotix SA reported €20.4 million in cash and closed a $50 million royalty financing with HealthCare Royalty, with an additional $21 million expected. This extends cash visibility to early 2028. Key developments include transferring NANORAY-312 study sponsorship to Johnson & Johnson, progress in the JNJ-1900 program, and advancement of the Curadigm Nanoprimer program. The news was published by Nanobiotix via GlobeNewswire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments